Biotech Values

[DewDiligence]

MNLO -47% on phase-3 failures of Serlopitant:

https://www.globenewswire.com/news-release/2020/04/06/2012003/0/en/Menlo-Therapeutics-Announces-Results-from-Two-Phase-3-Clinical-Trials-of-Serlopitant-for-the-Treatment-of-Pruritus-Associated-with-Prurigo-Nodularis.html

Study MTI-105 and Study MTI-106 did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis.

Not an enterprising clinical debut for a company that just completed a reverse-merger (#msg-154233939).